Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Predictors of In-Hospital Death in Patients with Lung Cancer Admitted for Acute Radiation Pneumonitis: A Healthcare Cost and Utilization Project (HCUP) AnalysisClinical Lung Cancer2021
2019 Feasibility of Dose Escalating [18F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate CancerAdvances in Radiation Oncology.  4:649-658. 2019
2019 Longitudinal assessment of anchored transponder migration following lung stereotactic body radiation therapyJournal of Applied Clinical Medical Physics.  20:17-22. 2019
2019 Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective TrialAdvances in Radiation Oncology.  4:90-95. 2019
2018 Safety and outcome measures of first-in-human intraperitoneal α radioimmunotherapy with 212 Pb-TCMC-Trastuzumab 2018
2018 Stereotactic Radiosurgery for Prostate Cancer Following Magnetic Resonance Imaging Directed Biopsy: A Multidisciplinary Approach with Case Examples.Cureus.  10:e2524. 2018
2016 Analysis of Predictive Factors for Acute Esophagitis in Lung Cancer Radiation Therapy. 2016
2016 Analysis of Predictive Factors for Pneumonitis in Lung Cancer Radiation Therapy. 2016
2016 Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined-modality therapy for muscle-invasive bladder cancer: A pooled analysis of NRG Oncology/RTOG 9906 and 0233 2016
2015 A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: Final results of radiation therapy oncology group phase 3 randomized trial NRG oncology RTOG 9902 2015
2015 Retention rate of electromagnetic navigation bronchoscopic placed fiducial markers for lung radiosurgeryAnnals of Thoracic Surgery.  100:1163-1166. 2015
2013 Effects of flattening filter-free and volumetric-modulated arc therapy delivery on treatment efficiency.Journal of Applied Clinical Medical Physics.  14:4328. 2013
2013 Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancerActa Oncologica.  52:1181-1188. 2013
2013 Effects of flattening filter-free and volumetric-modulated arc therapy delivery on treatment efficiencyJournal of Applied Clinical Medical Physics.  14:155-166. 2013
2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapyJournal of Applied Clinical Medical Physics.  14:4126. 2013
2013 Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapyJournal of Applied Clinical Medical Physics.  14:64-71. 2013
2013 Optimal planning target volume margins for elective pelvic lymphatic radiotherapy in high-risk prostate cancer patients.ISRN Oncology.  2013:941269. 2013
2010 Margin on Gross Tumor Volume and Risk of Local Recurrence in Head-and-Neck Cancer 2010
2009 Cancer of the tonsil presenting as central nervous system metastasis: A case report 2009
2006 Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study 2006

Principal Investigator On

  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2025
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2014 - 2017
  • Private Grant  awarded by COVIDIEN 2014 - 2015
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2009 - 2011
  • Investigator On

  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2026
  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019 - 2024
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2019 - 2023
  • A Phase II Study of Durvalumab (MEDI 4736) with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma  awarded by University of North Carolina at Chapel Hill 2020 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2020 - 2023
  • A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer  awarded by University of Florida 2020 - 2022
  • RTOG Foundation Master Service Agreement for Participation in Foundation Research: RTOG 3501 Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation  awarded by American College of Radiology 2012 - 2022
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2019 - 2022
  • Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial  awarded by University of Pennsylvania 2019 - 2021
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2015 - 2021
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2019
  • Private Grant  awarded by NOVOCURE, INC. 2017 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2014 - 2019
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC. 2018
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS 2016
  • Private Grant  awarded by SPECTRUM PHARMACEUTICALS, INC. 2013 - 2016
  • Private Grant  awarded by ELI LILLY AND COMPANY 2012 - 2015
  • Private Grant  awarded by ABBOTT LABORATORIES 2012 - 2014
  • Education And Training

  • Doctor of Medicine, Medical College of Ohio 2002
  • Mercy St. Vincent Medical Center, Internship 2003
  • UAB Hospital, Residency 2007
  • Full Name

  • Michael Dobelbower